Literature DB >> 27660681

Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

Jennifer E Sager1, John R Choiniere1, Justine Chang1, Alyssa Stephenson-Famy1, Wendel L Nelson1, Nina Isoherranen1.   

Abstract

Bupropion is a widely used antidepressant and the recommended CYP2B6 probe drug. However, current understanding of bupropion elimination pathways is limited. Bupropion has three active circulating metabolites, OH-bupropion, threohydrobupropion, and erythrohydrobupropion, but together with bupropion these metabolites and their conjugates in urine represent only 23% of the dose, and the majority of the elimination pathways of bupropion result in uncharacterized metabolites. The aim of this study was to determine the structures of the uncharacterized bupropion metabolites using human clinical samples and in vitro incubations. Three new metabolites, 4'-OH-bupropion, erythro-4'-OH-hydrobupropion, and threo-4'-OH-hydrobupropion, were detected in human liver microsome incubations and were isolated from human urine. The structures of the metabolites were confirmed via comparison of UV absorbance, NMR spectra, and mass spectral data to those of the synthesized standards. In total, these metabolites represented 24% of the drug related material excreted in urine.

Entities:  

Keywords:  Bupropion; aromatic hydroxylation; metabolites; structural characterization

Year:  2016        PMID: 27660681      PMCID: PMC5026406          DOI: 10.1021/acsmedchemlett.6b00189

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19.

Authors:  Yuan Chen; Hua-fen Liu; Liling Liu; Khanh Nguyen; Elliott B Jones; Adrian J Fretland
Journal:  Xenobiotica       Date:  2010-08       Impact factor: 1.908

2.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  Pharmacological significance of the species differences in bupropion metabolism.

Authors:  R M Welch; A A Lai; D H Schroeder
Journal:  Xenobiotica       Date:  1987-03       Impact factor: 1.908

4.  Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Authors:  M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

5.  Extended-release bupropion induced grand mal seizures.

Authors:  David J Rissmiller; Thomas Campo
Journal:  J Am Osteopath Assoc       Date:  2007-10

6.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

7.  Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.

Authors:  J W Findlay; J Van Wyck Fleet; P G Smith; R F Butz; M L Hinton; M R Blum; D H Schroeder
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Metabolism and kinetics of bupropion.

Authors:  D H Schroeder
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

9.  Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry.

Authors:  Aleksanteri Petsalo; Miia Turpeinen; Ari Tolonen
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

10.  Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice.

Authors:  Peter H Silverstone; Robert Williams; Louis McMahon; Rosanna Fleming; Siobhan Fogarty
Journal:  Ann Gen Psychiatry       Date:  2008-10-15       Impact factor: 3.455

View more
  6 in total

1.  Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.

Authors:  Yang Shen; Yang Yu; Wei Lai; Shuai Li; Zixuan Xu; Jiejing Jin; Xia Yan; Han Xing; Xijing Chen; Aizhen Xiong; Chunhua Xia; Jiake He; Kui Hong
Journal:  Pharm Res       Date:  2018-11-06       Impact factor: 4.200

2.  In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.

Authors:  Jennifer E Sager; Sasmita Tripathy; Lauren S L Price; Abhinav Nath; Justine Chang; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2016-11-09       Impact factor: 5.858

3.  Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.

Authors:  Evan D Kharasch; Amanda Crafford
Journal:  Clin Pharmacol Ther       Date:  2018-08-09       Impact factor: 6.875

4.  Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites.

Authors:  Emily E Fay; Lindsay C Czuba; Jennifer E Sager; Sara Shum; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Ther Drug Monit       Date:  2021-12-01       Impact factor: 3.681

Review 5.  The crucial role of multiomic approach in cancer research and clinically relevant outcomes.

Authors:  Miaolong Lu; Xianquan Zhan
Journal:  EPMA J       Date:  2018-02-21       Impact factor: 6.543

6.  Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.

Authors:  Jennifer E Sager; Lauren S L Price; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2016-08-05       Impact factor: 3.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.